Related Experiment Video

Updated: Dec 29, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K

MYC, MYCL, and MYCN as therapeutic targets in lung cancer

Daniel Massó-Vallés1, Marie-Eve Beaulieu1, Laura Soucek1,2,3,4

  • 1Peptomyc S.L., Edifici Cellex, Hospital Vall d'Hebron, Barcelona, Spain.

Expert Opinion on Therapeutic Targets
|February 1, 2020
PubMed

Insights

Targeting Myc, a key oncogene, offers a promising strategy for treating lung cancer, especially in cases of therapeutic resistance. Myc inhibitors show potential for clinical use, particularly when combined with immunotherapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer remains a leading cause of cancer mortality globally, with frequent recurrence despite advanced treatments.
  • The oncogene Myc plays a critical role in tumor progression and is often deregulated in lung cancer, correlating with poor prognosis and therapeutic resistance.

Purpose of the Study:

  • To review genomic and transcriptomic evidence of Myc family gene (MYC, MYCN, MYCL) amplification and overexpression in lung cancer.
  • To summarize the prognostic significance of Myc deregulation in lung cancer patients.
  • To explore the development and clinical potential of Myc inhibitors in lung cancer, including combination strategies.

Main Methods:

  • Systematic review of genomic and transcriptomic studies on Myc family genes in lung cancer.
  • Literature search for recent developments in Myc inhibitor research and preclinical/clinical testing.
  • Analysis of Myc's role in therapeutic resistance and immune suppression.

Main Results:

  • Evidence confirms MYC, MYCN, and MYCL amplification and overexpression in lung cancer patients.
  • Myc deregulation is significantly associated with poorer prognosis and treatment resistance.
  • Several Myc inhibitors have shown promise in experimental lung cancer models.

Conclusions:

  • Targeting Myc presents a significant therapeutic opportunity for lung cancer, addressing tumor progression and resistance.
  • Myc inhibitors are progressing towards clinical application, with potential for combination therapies.
  • Combining Myc inhibitors with immunotherapy is a promising avenue due to Myc's role in immune suppression.
Keywords:
Lung cancerMYCLMYCNMycMyc inhibitionNSCLCOmomycSCLCimmuno-oncology

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K